Drug Trial Radar · NCT00001213
Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis
Last checked: Nov 19, 2026Latest source record: Jul 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
328
Actual
Start
Apr 1986
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- National Eye Institute (NEI)NIH
- Sponsor type
- NIH
- First posted
- Nov 4, 1999
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cystinosis is an inherited disease that results in poor growth and kidney disease, among other things. The damage to the kidneys and other organs is thought to be due to accumulation of cystine inside the cells of various body tissues. This chemical also accumulates in the cornea-the covering of the eye over the pupil and iris. After 10 to 20 years, the corneas of some patients become so packed with crystals that the surfaces may become irregular, occasionally causing small, painful breaks. Patients enrolled in a NIH study on cystinosis are receiving the drug cysteamine. Taken by mouth, this drug reduces cystine in some tissues, but not in the cornea. This study began in 1986 to test whether cysteamine eye drops could prevent or reduce corneal cystine crystals in these patients. The drops have been very effective in removing crystals and reducing pain in patients who take the medication as directed. Patients who do not take the medication as prescribed do not benefit. After the effectiveness of the drops was proven, the main purpose was modified to continue to evaluate the long-term safety and effectiveness of cysteamine eye drops for treating cystine crystals in the corneas of patients with cystinosis until the drops are approved by the Food and Drug Administration (FDA). When the New Drug Application (NDA) for the Sigma-Tau standard formulation is granted, this protocol will be terminated.
Conditions
- Cystinosis
Interventions
CysteamineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Serious and Non-Serious Adverse EventsTime frame: Any Time Point up to 27 Years
- Number of Eyes With a Corneal Cystine Crystal Score (CCCS) ResponseTime frame: Any Time Point Up to 19 Years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.